
Please try another search
Investing.com -- Shares of UCB (EBR:UCB) rose more than 5% on Thursday after the drugmaker reported better-than-expected first-half results, lifted by strong U.S. sales of Bimzelx, and raised its 2025...
Investing.com -- Goldman Sachs has initiated coverage of UCB (EBR:UCB) with a “buy” rating and a 12-month price target of €250, representing a 46.5% upside from the current share price of...
Investing.com -- BofA Securities upgraded UCB SA to “buy” from “neutral,” raising its price objective to €225 from €210, citing strong commercial momentum for its inflammatory disease drug,...
Investing.com - TD Cowen maintained its Buy rating and €250.00 price target on UCB SA (BR:UCB) (OTC:UCBJY) on Monday, following positive feedback from hidradenitis suppurativa (HS) specialists...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review